<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107610</url>
  </required_header>
  <id_info>
    <org_study_id>Pediatric SBIR</org_study_id>
    <nct_id>NCT04107610</nct_id>
  </id_info>
  <brief_title>Normative Oculomotor and Vestibular Data in Pediatric Population</brief_title>
  <official_title>Development of a Pediatric Oculomotor and Vestibular Normative Database as an Essential Tool for Objective Evaluation of Concussion and Return-to-school/Play</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurolign</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurolign</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use a device called I-PortalÂ® Portable Assessment System&#xD;
      (I-PAS) to record eye movements in response to a number of visual and auditory stimuli&#xD;
      designed to evaluate neural brain pathways related to oculomotor, vestibular, reaction time&#xD;
      and cognitive (OVRT-C) development. The goal of this research is to collect normative data&#xD;
      for the OVRT-C tests from a healthy pediatric population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normative data for I-PAS tests</measure>
    <time_frame>3 years</time_frame>
    <description>Accuracy and gain across age: measurements of eye displacement versus stimulus displacement in saccadic and smooth pursuit tasks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Goggle evaluation</measure>
    <time_frame>3 years</time_frame>
    <description>Short questionnaire consisting of 6 questions to assess the look, feel and weight of the goggles. 5 questions are Yes/No (0/1) and one question is on a rating from 0 to 3. The total score from these questions represents an evaluation of goggle comfort. The score can be between 0-8, where a score of 0 is indicative of a very good comfort level and a score of 8 of a low comfort level.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>I-PAS</intervention_name>
    <description>I-PAS is a portable, head-mounted display goggle system with integrated eye tracking technology. I-PAS records eye movements in response to visual and auditory stimuli.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females age 6 to 18 years of all races.&#xD;
&#xD;
          -  Parental/guardian permission (informed consent) and child assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of head injury characterized by any of the following:&#xD;
&#xD;
               1. Resulting from penetrating trauma&#xD;
&#xD;
               2. Resulting from an automobile accident with significant associated injuries&#xD;
&#xD;
               3. Associated with a Glasgow Comma Scale Score of less than 13 at the time of injury&#xD;
&#xD;
               4. Associated with a loss of consciousness period greater than 30 minutes&#xD;
&#xD;
               5. Judged to be more than mild by medical staff&#xD;
&#xD;
               6. Requiring admission to the hospital for any reason&#xD;
&#xD;
               7. Associated with subdural or epidural hemorrhage&#xD;
&#xD;
               8. Persons with a previous history of mTBI in the past and who were symptomatic&#xD;
                  prior to current injury&#xD;
&#xD;
          -  Pregnancy, as documented by last menstrual period at study visits&#xD;
&#xD;
          -  Implants: Persons implanted with an electrical and/or neurostimulator device,&#xD;
             including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator,&#xD;
             deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant,&#xD;
             metal cervical spine hardware&#xD;
&#xD;
          -  Diagnosed with attention deficit hyperactivity disorder (ADHD), autism spectrum&#xD;
             disorder, major depression, hypochondriasis, bipolar disorders, or schizophrenia.&#xD;
&#xD;
          -  Presence of severe aphasia or inability to follow commands and give independent&#xD;
             responses&#xD;
&#xD;
          -  Documented neurodegenerative disorders (Multiple sclerosis, Parkinson's, Alzheimer's,&#xD;
             Huntington)&#xD;
&#xD;
          -  Past history of seizures or convulsions&#xD;
&#xD;
          -  Prior disorders of hearing and balance including:&#xD;
&#xD;
               1. Meniere's disease&#xD;
&#xD;
               2. Multiple sclerosis&#xD;
&#xD;
               3. Vestibular neuritis&#xD;
&#xD;
               4. Vestibular schwannoma&#xD;
&#xD;
               5. Sudden sensorineural hearing loss&#xD;
&#xD;
               6. History of ear operation other than myringotomy and tube placement in the past&#xD;
&#xD;
               7. Acute or chronic disease of middle ear (infections, otitis)&#xD;
&#xD;
          -  History of cerebrovascular disorders including stroke, brainstem or cerebellar&#xD;
             dysfunction within the last 3 months&#xD;
&#xD;
          -  Systemic disorders that include chronic renal failure, cirrhosis of the liver,&#xD;
             autoimmune disease, heart disease, lung disease, severe arthritis, diabetes,&#xD;
             hypertension&#xD;
&#xD;
          -  Repeated history of syncope&#xD;
&#xD;
          -  Past or concomitant treatment with ototoxic chemotherapy&#xD;
&#xD;
          -  Previous contraindicating surgeries at the discretion of the study physician&#xD;
&#xD;
          -  Aminoglycosides in the past 6 months given via systemic or transtympanic&#xD;
             administration&#xD;
&#xD;
          -  Concomitant treatment with any of the followings within the last 24 hours prior to&#xD;
             testing if more than 2 doses have been taken:&#xD;
&#xD;
               1. Antihistamines: e.g. diphenhydramine, cyclizine, dimenhydrinate, meclizine,&#xD;
                  hydroxyzine, promethazine,&#xD;
&#xD;
               2. For ADHD and narcolepsy: e.g. Concerta, Daytrana, Methylin, Ritalin, Ritalin LA,&#xD;
                  Metadate ER, Aptensio XR, Cotempla XR-ODT, QuilliChew ER, and Quillivant XR&#xD;
&#xD;
               3. For schizophrenia and other mental diseases: e.g. Phenothiazines&#xD;
&#xD;
               4. Specific antibiotics: e.g. ethambutol, gentamycin&#xD;
&#xD;
               5. Anticonvulsant medications: e.g. topiramate&#xD;
&#xD;
          -  Currently suffering from dehydration&#xD;
&#xD;
          -  History or suspicion of substance abuse or addiction&#xD;
&#xD;
          -  Acute alcohol intoxication&#xD;
&#xD;
          -  Playing professional sports at the Olympic/league level&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aura Kullmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuro Kinetics/Neurolign</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ALEXANDER D KIDERMAN, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuro Kinetics/Neurolign</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aura Kullmann, PhD</last_name>
    <phone>4129636649</phone>
    <email>aura.kullmann@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ALEXANDER D KIDERMAN, PhD</last_name>
    <phone>4129636649</phone>
    <email>AKIDERMAN@NEURO-KINETICS.COM</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>MICHAEL HOFFER, PhD</last_name>
      <phone>305-243-1484</phone>
      <email>michael.hoffer@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Edward Snell, MD</last_name>
      <email>Edward.SNELL@ahn.org</email>
    </contact>
    <contact_backup>
      <last_name>Angela Filmore</last_name>
      <phone>412-359-8805</phone>
      <email>Angela.Finamore@ahn.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oculomotor,</keyword>
  <keyword>vestibular,</keyword>
  <keyword>concussion,</keyword>
  <keyword>mild traumatic brain injury</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

